Why the study?
Does genetic ablation of Cat2 reduce iNOS-mediated NO production in astrocytes?
Does genetic ablation of Cat2 reduce iNOS-mediated NO production in astrocytes?
Genetic ablation of Cat2 significantly reduces iNOS-mediated NO production in astrocytes, suggesting CAT2 transporter manipulation could be a therapeutic target for neurological disorders.
No takes yet. Share an insight, caveat, or question.
May support Cat2 targeting in neuroinflammation; leaves open translation from rodent astrocytes to human neurological disorders.
Manner et al. (2003) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: